Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 20/20 | 0.59 |
| ▸ | BRAF | P15056 | 20/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | ARAF | P10398 | 1/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.50 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24401048 | 0.92 | RAF1 (0.63) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24400687 | 0.91 | BRAF (0.62) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24401211 | 0.88 | BRAF (0.49) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL29747073 | 0.86 | RAF1 (0.56) | RAF1BRAF | |
| SCHEMBL24401051 | 0.86 | RAF1 (0.56) | RAF1BRAF | |
| SCHEMBL24400630 | 0.86 | RAF1 (0.60) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24401050 | 0.86 | RAF1 (0.63) | RAF1BRAF | |
| SCHEMBL24401006 | 0.83 | BRAF (0.61) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24400998 | 0.82 | BRAF (0.73) | RAF1BRAFPDGFRBARAFDDR1 | |
| SCHEMBL24401009 | 0.82 | RAF1 (0.62) | RAF1BRAFPDGFRBARAFDDR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | Eternity Bioscience Inc. | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135539-A1 | BIARYL AMIDE COMPOUNDS, PREPARATION METHODS AND MEDICAL APPLICATIONS THEREOF | BRAF, NRAS, RAF1 | RAF1 3/4885BRAF 1/4885PDGFRB 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.